II. Indications
- Parkinsonism-related Psychosis (Hallucinations, Delusions)
III. Dosing
- Start 34 mg orally daily
- Lower dose to 10 mg daily if on CYP3A4 Inhibitors
IV. Mechanism
VI. Adverse Effects
VII. Safety
- Unknown safety in pregnancy
- Unknown safety in Lactation
VIII. Resources
IX. References
- (2016) Med Lett Drugs Ther 58(1510): 160-5
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 42-3
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C510793 |
English | N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide, Pimavanserin, PIMAVANSERIN |